EMA to consider expanding use of Merck/Pfizer’s Bavencio
The regulator will assess its safety and efficacy as a treatment for bladder cancer
Read More
Tag: JAVELIN
Merck’s Bavencio hits targets in bladder cancer interim analysis
Last year the drug disappointed in the Phase III JAVELIN Gastric 100 study, but has pulled itself back with new urothelial carcinoma data.
Read More
Merck, Pfizer pull the plug on ovarian cancer trial
Merck and Pfizer are pulling the plug on a late-stage trial assessing the potential of their PD-L1 antibody avelumab in the front-line maintenance setting for ovarian cancer.
Read More
EMA validates Bavencio for review in advanced RCC
European regulators have validated Merck’s application Bavencio for review in kidney cancer.
Read More
Pfizer, Merck to terminate Phase III Bavencio study
Pfizer and Merck KGaA have announced that they will be terminating the Phase III JAVELIN Ovarian 100 study of Bavencio, as the data did not support the study’s initial hypothesis.
Read More
Merck, Pfizer launch Bavencio for rare skin cancer
Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).
Read More
Pfizer, Merck launch late-stage ovarian cancer trial
Pfizer and Germany’s Merck have kicked off a large-scale, late-stage study assessing their immunotherapy avelumab in ovarian cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
